Literature DB >> 26017458

Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.

Krista N Larson1, Amy L Gagnon1, Melissa D Darling2, James W Patterson2, Thomas G Cropley1.   

Abstract

IMPORTANCE: Nephrogenic systemic fibrosis (NSF) is a fibrosing skin disorder that develops in patients with kidney failure and has been linked to exposure to gadolinium-containing contrast agents. The time between exposure to gadolinium and the initial presentation of NSF is typically weeks to months but has been documented to be as long as 3½ years. We report a case of NSF developing 10 years after exposure to gadolinium. OBSERVATIONS: A long-term hemodialysis patient was exposed to gadolinium several times between 1998 and 2004 during magnetic resonance angiography of his abdominal vessels and arteriovenous fistula. In 2014, he was seen at our clinic with new dermal papules and plaques. Biopsy of affected skin showed thickening of collagen, CD34+ spindle cells, and increased mucin in the dermis, supporting the diagnosis of NSF. CONCLUSIONS AND RELEVANCE: The clinical history and histopathological features of this case support the diagnosis of NSF 10 years after exposure to gadolinium. Although the use of gadolinium contrast agents in patients with kidney failure has markedly decreased, patients with exposure to gadolinium years to decades previously may manifest the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26017458     DOI: 10.1001/jamadermatol.2015.0976

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  10 in total

Review 1.  Gadolinium-based contrast agents: did we miss something in the last 25 years?

Authors:  Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi; Yuri Errante; Rosario Francesco Grasso
Journal:  Radiol Med       Date:  2015-12-26       Impact factor: 3.469

2.  Metal Nanoparticles in Infection and Immunity.

Authors:  John K Crane
Journal:  Immunol Invest       Date:  2020-06-11       Impact factor: 3.657

Review 3.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

4.  Non-contrast MRI methods as a tool for the pre-operative assessment and surveillance of the arterio-venous fistula for haemodialysis.

Authors:  Conor J MacDonald; Stephen Gandy; Eilidh C M Avison; Shona Matthew; Rose Ross; John G Houston
Journal:  MAGMA       Date:  2018-08-21       Impact factor: 2.310

5.  The extra miles on preventing nephrogenic systemic fibrosis.

Authors:  A Adhipatria P Kartamihardja; Yoshito Tsushima
Journal:  Quant Imaging Med Surg       Date:  2019-11

Review 6.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

Review 7.  Safety and technique of ferumoxytol administration for MRI.

Authors:  Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir
Journal:  Magn Reson Med       Date:  2016-02-18       Impact factor: 4.668

Review 8.  T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Authors:  Nigel Hoggard; Giles H Roditi
Journal:  Br J Radiol       Date:  2016-10-19       Impact factor: 3.039

Review 9.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

10.  A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.

Authors:  Sadichhya Lohani; Jon Golenbiewski; Abhishek Swami; Alexandra Halalau
Journal:  BMJ Case Rep       Date:  2017-10-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.